Alfa Wassermann Partners with Theravance to Develop Velusetrag for Gastroparesis
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 10 (Table of Contents)
Published: 25 Oct-2012
DOI: 10.3833/pdr.v2012.i10.1824 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to bolster its gastroenterology portfolio, Alfa Wassermann has partnered with Theravance to advance the development of velusetrag (TD-5108), an oral 5-HT4 agonist in development for gastrointestinal motility disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS